ArticleiScience2026
BUB1 regulates cell proliferation and apoptosis in cervical cancer by AKT signaling and autophagosome-lysosome fusion via ACTN1.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) is the fourth most common cancer in women worldwide. New therapeutic targets are urgently needed considering the inadequacy of current treatments. In this study, we investigated the role of budding uninhibited by benzimidazoles 1 (BUB1) in CC and identified a dual mechanism through which BUB1 promotes tumor progression. BUB1 interacted with α-actinin 1 (ACTN1) and regulated its subcellular distribution: BUB1 maintained ACTN1 at focal adhesions to sustain AKT activation, while facilitating ACTN1-positive comet tail-propelled autophagosome trafficking toward lysosomes. Autophagosome accumulation elevated reactive oxygen species (ROS), which causally contributed to apoptosis, as demonstrated by NAC rescue experiments. Kinase-dead BUB1 failed to rescue these phenotypes. Furthermore, kinase inhibitor of BUB1, 2OH-BNPP1, phenocopied the ACTN1 intracellular localization of BUB1 knockdown, confirming the requirement for BUB1 kinase activity. 2OH-BNPP1 treatment significantly reduced the growth of subcutaneous xenograft tumors, highlighting the potential of BUB1 as a promising therapeutic target for CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.